Kristie L. Kahl

A slower walking pace among older adults with blood cancer can be a sign of frailty – which could be useful to know when tailoring one’s care to increase survival and lower hospitalizations.

The Food and Drug Administration approved Turalio to treat patients diagnosed with a group of rare, benign tumors.

In this week’s episode of the “CURE Talks Cancer” podcast, we spoke with a caregiver about support for others taking care of a loved one with cancer through a letter she wrote to her younger self.

Following the Food and Drug Administration’s approval of Nubeqa, men with non-metastatic castration-resistant prostate cancer now have an earlier more precise treatment option.

The Food and Drug Administration has approved Keytruda for recurrent locally advanced or metastatic squamous cell carcinoma of the esophagus in certain patients.

The Food and Drug Administration granted a priority review to Nubeqa for the treatment of men with non-metastatic castration-resistant prostate cancer.

Here is a list of the recent trial initiations that occurred within the cancer space in July.

CURE® spoke with one expert about the various treatment options and current clinical trials available to patients with mesothelioma, as well as what they have to look forward to in the future.

CURE spoke with one expert about mesothelioma symptoms that patients can be on the lookout for, as well as how to be knowledgeable about certain risk factors.

In this week’s episode of the “CURE Talks Cancer” podcast, we spoke with ex-NFL kicker Rolf Benirschke about being a grateful patient and how one can choose to be the victim or the victor in their diagnosis.

The Food and Drug Administration granted a priority review to a new drug application for the accelerated approval of tazemetostat to treat metastatic or locally advanced epithelioid sarcoma not eligible for curative surgery.

With the Food and Drug Administration’s approval of Ruxience, a biosimilar to Rituxan, patients with certain types of non-Hodgkin lymphoma and chronic lymphocytic leukemia may have improved access to a more affordable treatment option.

Treatment with fedratinib may lead to clinically meaningful responses among patients with myelofibrosis who were previously treated with Jakafi, according to an updated analysis of the phase 2 JAKARTA2 study.

Karen, who received her bladder cancer diagnosis in 2010, was faced with a similar challenge after her husband was diagnosed with the same disease just six years later.

In this week’s episode of the “CURE Talks Cancer” podcast, we spoke with a bladder cancer survivor turned caregiver about the advice she would give her newly-diagnosed self.

While half of women with gynecologic cancer reported experiencing significant fatigue during treatment, only 8% of survivors had symptoms regress without intervention.

Long-term survivors of pediatric neuroblastoma may be at an increased risk for neurocognitive impairment – in particular, due to age at diagnosis and the type of treatment received.

An oncology dietitian offered advice on how to improve appetite and eat healthy before, during and after treatment for gastrointestinal cancers.

A glioblastoma (GBM)-specific app, called OurBrainBank, efficiently collected patients’ symptoms – offering many hope for future research, according to founder Jessica Morris.

Cancer Blows, an event by The Ryan Anthony Foundation, offers hope for many with cancer – all while raising awareness for multiple myeloma.

Many patients wonder why their chemotherapy infusions take so long, so three health care professionals explained the process from start to finish.

In this week’s episode of “CURE Talks Cancer,” we spoke with a melanoma survivor who wishes she knew at diagnosis what her cancer journey would do for her – not to her.

In assessing the quality of family cancer history entered into electronic health records, researchers found that such reporting was suboptimal – highlighting the need to optimize online collection with a provider-free approach.

Increased tumor mutation burden (TMB), which is associated with more inflammation, may be a factor in determining which patients with lung cancer are at higher risk for depression.

In the second part of our Q&A with Chris Williams, of the Multiple Myeloma Research Foundation, we spoke with him about the past, present and future of the myeloma landscape.

In the first part of our Q&A with Chris Williams, of the Multiple Myeloma Research Foundation, we spoke with him on the current initiatives and resources available to patients.

Routine use of prophylactic radiotherapy in patients with malignant pleural mesothelioma is unnecessary following a chest wall procedure, according to multicenter, open-label, phase 3, randomized controlled trial findings published in the Journal of Clinical Oncology.

Maintenance therapy with defactinib failed to improve survival following front-line chemotherapy in patients with merlin-low malignant pleural mesothelioma, according to results from the phase 2 COMMAND trial.

A novel imaging test developed at UT Southwestern may help to determine which patients with kidney cancer would benefit from treatment with immunotherapy.

While advances have been made in the treatment landscape of hepatocellular carcinoma, researchers are now looking into the optimal sequence for which patients should be treated.